Targeted therapy for fusion-driven high-risk acute leukemia
Targeted therapy for fusion-driven high-risk acute leukemia
复制标题
DOI：
10.1182/blood-2018-04-784157
复制
发表时间：
2018-09-20
期刊：
影响因子：
20.3
通讯作者：
Stegmaier, Kimberly
中科院分区：
文献类型：
--
作者：
Pikman, Yana;Stegmaier, Kimberly
尽管急性白血病的药物开发不断取得进展，但在过去十年中，某些亚型患者的结局并未发生显著变化。复发性染色体易位长期以来被认为是白血病的驱动事件，许多这些致癌融合预示着高风险疾病。对这些融合的分子基础的更好理解，加上新的化学方法，现在为这些融合驱动的白血病治疗提供了新的机会。
Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.